2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5708 Pre-existing CX3CR1⁺ cytotoxic CD4⁺ T cells sustain durable responses to bispecific antibodies in multiple myeloma

Yating Li, MD, PhD, Wenqiang Yan2, Lu-Gui Qiu, PhD3, Gang An, MD4
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
Background
T-cell–engaging bispecific antibodies (BsAbs) have significantly improved outcomes in relapsed/refractory multiple myeloma (RRMM), yet determinants of durable response remain undefined. We performed longitudinal single-cell transcriptomic and TCR/BCR profiling to identify cellular and clonal programs associated with durable response.
Methods
We performed longitudinal single-cell RNA, TCR, and BCR sequencing on 23 bone marrow samples collected before and after BsAb therapy from 12 RRMM patients. Patients were stratified into long-term responders (LR, ≥18 months; n=6) and short-term responders (SR, <18 months; n=6).
Results
After quality control, 171,485 cells were retained for downstream analysis. BsAb therapy induced expansion of CX3CR1? cytotoxic CD8? T cells (CD8 TE-CTL) in both LR and SR patients, without association with response duration. In contrast, CX3CR1? cytotoxic CD4? T cells (CD4 TE-CTL) selectively expanded in LR patients and exhibited a terminally differentiated cytotoxic transcriptional program. Trajectory analysis revealed preferential differentiation of TCF7? stem-like CD4? T cells into non-exhausted TE-CTL cells in LR patients, whereas SR patients accumulated TCF7? stem-like cells without terminal effector differentiation. Single-cell TCR profiling further revealed that CD4 TE-CTL populations in LR patients were predominantly composed of shared clonotypes detected both before and after treatment; in contrast, SR patients were enriched for pre-treatment-only clonotypes. Shared clonotypes exhibited enhanced cytotoxic and interferon-response signatures, indicating functional reactivation of pre-existing effector populations during durable response. Concordantly, post-treatment myeloid subsets in LR patients were enriched for interferon-response and antigen-presentation programs, suggesting coordinated T cell–myeloid activation.
Conclusions
Durable responses to BsAb therapy are associated with reactivation and persistence of pre-existing CX3CR1? cytotoxic CD4? T-cell clonotypes. These findings identify a previously underappreciated CD4? cytotoxic T-cell axis supporting durable anti-myeloma immunity.
Yating Li, MD, PhD: No relevant conflicts of interest to declare.